Leptin Dysfunction and Alzheimer’s Disease: Evidence from Cellular, Animal, and Human Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
There is accumulating evidence from epidemiological studies that changes in body weight are associated with Alzheimer’s disease (AD) from mid-life obesity increasing the risk of developing AD to weight loss occurring at the earliest stages of AD. Therefore, factors that regulate body weight are likely to influence the development and progression of AD. The adipocyte-derived hormone leptin has emerged as a major regulator of body weight mainly by activating hypothalamic neural circuits. Leptin also has several pleotropic effects including regulating cognitive function and having neuroprotective effects, suggesting a potential link between leptin and AD. Here, we will examine the relationship between leptin and AD by reviewing the recent evidence from cellular and animal models to human studies. We present a model where leptin has a bidirectional role in AD. Not only can alterations in leptin levels and function worsen cognitive decline and progression of AD pathology, but AD pathology, in of itself, can disrupt leptin signaling, which together would lead to a downward spiral of progressive neurodegeneration and worsening body weight and systemic metabolic deficits. Collectively, these studies serve as a framework to highlight the importance of understanding the molecular mechanisms underlying the body weight and systemic metabolic deficits in AD, which has the potential to open new avenues that may ultimately lead to novel therapeutic targets and diagnostic tools.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“The accumulation of Ab and tau eventually lead to neuronal dysfunction and cognitive decline as seen in the mild cognitive impairment (MCI) or the symptomatic predementia phase of AD (Albert et al. 2011).”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 3×
“It is now recognized that the neuropathological abnormalities associated with AD such as the accumulation of Ab and tau begin decades before the initial presentation of cognitive symptoms during the preclinical stage of AD (Sperling et al. 2011).”
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Maffei, M., Halaas, J., Ravussin, E., Pratley, R. E., Lee, G. H., Zhang, Y., Fei, H., Kim, S., Lallone, R., Ranganathan, S., et al. (1995) · Nature Medicine · doi:10.1038/nm1195-1155 · Cited by 3,725
Congenital leptin deficiency is associated with severe early-onset obesity in humans
Montague, C. T., Farooqi, I. S., Whitehead, J. P., Soos, M. A., Rau, H., Wareham, N. J., Sewter, C. P., Digby, J. E., Mohammed, S. N., Hurst, J. A., et al. (1997) · Nature · doi:10.1038/43185 · Cited by 2,936
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187 · cited 1×
“Similar results have been consistently found in several other epidemiological studies (Leibson et al. 1997; Peila et al. 2002; Biessels et al. 2006).”
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“…cause morbid obesity and severe metabolic derangements such as diabetes and insulin resistance in both rodents and humans (Zhang et al. 1994; Montague et al. 1997) with reversal of the body weight and metabolic deficits by exogenous leptin treatment (Halaas et al. 1995; Farooqi et al. 1999).”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 13×
“Further confirming the strong association between low body weight and AD, several studies have found that low body mass index (BMI) is associated with both worsening AD pathology in postmortem brains (Buchman et al. 2006; Vidoni et al. 2011) and worsening CSF biomarkers (tau and Ab1-42) (Ewers et al. 2012).”
InfluentialAlzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Despite extensive efforts, recent AD clinical trials have been largely disappointing with no new AD drug approved by the US Food and Drug Administrations (FDA) since memantine in 2003 (Cummings et al. 2014).”
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · cited 1×
“Similar results have been consistently found in several other epidemiological studies (Leibson et al. 1997; Peila et al. 2002; Biessels et al. 2006).”
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“In one study investigating the accuracy of the clinical diagnosis of AD at National Institute on Aging Alzheimer Disease Centers, the sensitivity in diagnosing AD ranged from 70.9 to 87.3 % while the specificity ranged from 44.3 to 70.8 % (Beach et al. 2012).”
InfluentialLeptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038 · cited 2×
“Additionally, chronic peripheral leptin treatment can reverse the severe metabolic derangements such as insulin resistance, hyperglycemia , and hepatic steatosis in both rodent models and humans with severe lipodystrophy (Shimomura et al. 1999; Petersen et al. 2002).”
Schwartz, M. W., Baskin, D. G., Bukowski, T. R., Kuijper, J. L., Foster, D., Lasser, G., Prunkard, D. E., Porte, D., Woods, S. C., Seeley, R. J., et al. (1996) · Diabetes · doi:10.2337/diab.45.4.531 · Cited by 904 · cited 4×
“In addition, leptin receptors are found not only in the hypothalamus, which is the major site of action of leptin on body weight regulation, but leptin receptors are also expressed in the cortex and hippocampus, two major areas affected in AD (Schwartz et al. 1996b; Hâkansson et al. 1998).”
InfluentialCentral obesity and increased risk of dementia more than three decades later
Whitmer, R. A., Gustafson, D. R., Barrett-Connor, E., Haan, M. N., Gunderson, E. P., & Yaffe, K. (2008) · Neurology · doi:10.1212/01.wnl.0000306313.89165.ef · Cited by 803
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 2×
“Additionally, chronic peripheral leptin treatment can reverse the severe metabolic derangements such as insulin resistance, hyperglycemia , and hepatic steatosis in both rodent models and humans with severe lipodystrophy (Shimomura et al. 1999; Petersen et al. 2002).”
Acute stimulation of glucose metabolism in mice by leptin treatment
Kamohara, S., Burcelin, R., Halaas, J. L., Friedman, J. M., & Charron, M. J. (1997) · Nature · doi:10.1038/38717 · Cited by 708 · cited 2×
“Several studies over the years have demonstrated in different rodent models that exogenous leptin administration can improve glucose metabolism by increasing insulin sensitivity (Kamohara et al. 1997; Coppari and Bjørbaek 2012; Knights et al. 2014).”
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700 · cited 1×
“Similar results have been consistently found in several other epidemiological studies (Leibson et al. 1997; Peila et al. 2002; Biessels et al. 2006).”
Human Leptin Levels Are Pulsatile and Inversely Related to Pituitary–Ardenal Function
Licinio, J., Mantzoros, C., Negrão, A. B., Cizza, G., Wong, M.-L., Bongiorno, P. B., Chrousos, G. P., Karp, B., Allen, C., Flier, J. S., et al. (1997) · Nature Medicine · doi:10.1038/nm0597-575 · Cited by 632 · cited 1×
“As leptin is secreted in a pulsatile and circadian manner, the amount of circulating leptin is dynamic and changes throughout the day with the lowest levels at mid-afternoon and the highest levels at midnight (Licinio et al. 1997; Park and Ahima 2015).”
Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease
Musiek, E. S., Xiong, D. D., & Holtzman, D. M. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2014.121 · Cited by 529 · cited 2×
“physiological and behavioral functions that are associated with the hypothalamus such as sleep and circadian rhythm (Musiek et al. 2015; Ishii and Iadecola 2015), other hypothalamic cell populations are likely to be affected by Ab and tau.”
Stewart, R., Masaki, K., Xue, Q.-L., Peila, R., Petrovitch, H., White, L. R., & Launer, L. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.55 · Cited by 478
Alzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473
Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents
Li, X.-L., Aou, S., Oomura, Y., Hori, N., Fukunaga, K., & Hori, T. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00162-8 · Cited by 440
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · cited 1×
“Since leptin treatment with an adjunct such as amylin has been shown to restore the responsiveness of leptin (Roth et al. 2008), a combination therapy approach can be considered in those individuals who have evidence of both central leptin resistance and AD.”
Association of Plasma Leptin Levels With Incident Alzheimer Disease and MRI Measures of Brain Aging
Lieb, W. (2009) · JAMA · doi:10.1001/jama.2009.1836 · Cited by 428
Leptin signaling in astrocytes regulates hypothalamic neuronal circuits and feeding
Kim, J. G., Suyama, S., Koch, M., Jin, S., Argente-Arizon, P., Argente, J., Liu, Z.-W., Zimmer, M. R., Jeong, J. K., Szigeti-Buck, K., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3725 · Cited by 336
Cao, D., Lu, H., Lewis, T. L., & Li, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703561200 · Cited by 336 · cited 2×
“…worsens AD pathology, as inducing type 1 diabetes by streptozotocin treatment or insulin resistance by feeding a high-fat diet or sucrose-sweetened water in AD mouse models exacerbates both the amyloid and tau pathology (Cao et al. 2007; Ke et al. 2009; Julien et al. 2010; Kim and Feldman 2015).”
Leptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327
White, H., Pieper, C., & Schmader, K. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb04537.x · Cited by 323 · cited 1×
“Furthermore , the weight loss in AD correlates with disease morbidity and mortality (White et al. 1996, 1998).”
Obesity‐related leptin regulates Alzheimer's Aβ
Fewlass, D. C., Noboa, K., Pi‐Sunyer, F. X., Johnston, J. M., Yan, S. D., & Tezapsidis, N. (2004) · The FASEB Journal · doi:10.1096/fj.04-2572com · Cited by 308 · cited 4×
“Exogenous leptin treatment has been demonstrated in vitro to increase the LRP1 mediated uptake of ApoE bound Ab in a dose-dependent manner (Fewlass et al. 2004).”
InfluentialReview on leptin and adiponectin responses and adaptations to acute and chronic exercise
Bouassida, A., Chamari, K., Zaouali, M., Feki, Y., Zbidi, A., & Tabka, Z. (2010) · British Journal of Sports Medicine · doi:10.1136/bjsm.2008.046151 · Cited by 290
High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Émond, V., Julien, P., & Calon, F. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.022 · Cited by 288
Making insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219
Overweight in midlife and risk of dementia: a 40-year follow-up study
Hassing, L. B., Dahl, A. K., Thorvaldsson, V, Berg, S., Gatz, M., Pedersen, N. L., & Johansson, B. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.104 · Cited by 197 · cited 1×
“Several epidemiological studies have consistently shown that mid-life obesity is a risk factor for developing AD independent of other known metabolic factors such as hypertension and diabetes (Whitmer et al. 2008; Hassing et al. 2009; Xu et al. 2011; Emmerzaal et al. 2015).”
Weng, Z., Signore, A. P., Gao, Y., Wang, S., Zhang, F., Hastings, T., Yin, X.-M., & Chen, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705426200 · Cited by 163 · cited 2×
“Leptin also exerts a cytoprotective effect against the mitochondrial neurotoxin 1-methyl-4-pyri- dinium (MPP?) as well as 6-hydroxydopamine, both experimental models of Parkinson disease (Lu et al. 2006; Weng et al. 2007).”
Early effects of a hypocaloric, Mediterranean diet on laboratory parameters in obese individuals
Greco, M., Chiefari, E., Montalcini, T., Accattato, F., Costanzo, F. S., Pujia, A., Foti, D., Brunetti, A., & Gulletta, E. (2014) · Mediators of Inflammation · doi:10.1155/2014/750860 · Cited by 98 · cited 1×
“Since diet and exercise can potentially influence the circulating leptin levels and central leptin sensitivity (Bouassida et al. 2010; Greco et al. 2014; Balaskó et al. 2014), leptin may serve as one of the intermediary signals linking diet and/or exercise to AD.”
Obesity exacerbates chemically induced neurodegeneration
Sriram, K., Benkovic, S. A., Miller, D. B., & O’Callaghan, J. P. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00306-8 · Cited by 78 · cited 2×
“2008) and increased morbidity and worse outcomes after methamphetamine and kainic acid neurotoxicity (Sriram et al. 2002).”
Cited by
The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer’s Disease
Forny-Germano, L., De Felice, F. G., & Vieira, M. N. D. N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01027 · Cited by 297
Obesity and ageing: Two sides of the same coin
Tam, B. T., Morais, J. A., & Santosa, S. (2020) · Obesity Reviews · doi:10.1111/obr.12991 · Cited by 253
Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin
Flores-Cordero, J. A., Pérez-Pérez, A., Jiménez-Cortegana, C., Alba, G., Flores-Barragán, A., & Sánchez-Margalet, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095202 · Cited by 212
“As we will see below, leptin is involved in various aspects of cognition, neurogenesis, neuroprotection, synaptic plasticity, and structural changes [57,62], which is not surprising given its access from the periphery to the CNS, the number of leptin receptors, and its wide distribution in the brain.”
BackgroundInfluential(2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2019.07.012 · Cited by 46
de Carvalho, T. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.332126 · Cited by 36
Metadata
- Authors
- McGuire, M. J., & Ishii, M.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2016-03
- Volume
- 36
- Issue
- 2
- Pages
- 203-217
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- OpenAlex
- W2300004503
- Cited by
- 125
- References
- 40
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.